Perceptive Advisors GMED Position
Exited3-Fund ConvergencePerceptive Advisors exited their position in GLOBUS MEDICAL INC (GMED) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
GMED is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About GLOBUS MEDICAL INC
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Full company profile →Short Interest
2.3%
2.9 days to cover
Perceptive Advisors GMED Position History
Frequently Asked Questions
Does Perceptive Advisors own GMED?
No. Perceptive Advisors exited their position in GLOBUS MEDICAL INC (GMED) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own GMED?
3 specialist biotech hedge funds currently hold GMED, including RTW Investments, Driehaus Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy GMED?
Perceptive Advisors's position in GMED was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's GMED position increasing or decreasing?
Perceptive Advisors completely exited their GMED position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GMEDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →